| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9308204 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| US9439902 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
Segluromet is owned by Msd Sub Merck.
Segluromet contains Ertugliflozin; Metformin Hydrochloride.
Segluromet has a total of 3 drug patents out of which 0 drug patents have expired.
Segluromet was authorised for market use on 19 December, 2017.
Segluromet is available in tablet;oral dosage forms.
Segluromet can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Drug patent challenges can be filed against Segluromet from 19 December, 2021.
The generics of Segluromet are possible to be released after 21 October, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date:
19 December, 2021
Market Authorisation Date:
19 December, 2017Treatment:
An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetesDosage:
TABLET;ORAL
More Information on Dosage
SEGLUROMET family patents
